Latest Oncology News

FDA Grants Breakthrough Therapy Designation to Talquetamab for R/R Myeloma

June 29, 2022

The FDA has granted breakthrough therapy designation to talquetamab for the treatment of previously-treated adult patients with relapsed or refractory multiple myeloma based on positive results from the phase 1/2 MonumenTAL-1 study.